Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMDE005 in EGFR-positive advanced solid tumors
ChiCTR2400090635Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CMDE005 in Nonhematologic neoplasms, pancreatic cancer (PC), non-small cell lung cancer (NSCLC) and 3 more, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
CMDE005
03
Conditions
Nonhematologic neoplasmspancreatic cancer (PC)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400090635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090635.